Vasomotor Symptoms

Unraveling Menopause: Symptom Prevalence and Severity Across the Transition—Insights from the Australian Women’s Midlife Years (AMY) Study

By MedXY 08/22/2025

The AMY Study highlights vasomotor symptoms, particularly hot flushes, as key indicators of perimenopause onset, challenging traditional cycle-based definitions and underscoring the need for tailored symptom management across diverse reproductive stages.

OB/GYN & Women's Health Oncology Specialties

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY 08/21/2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

AI OB/GYN & Women's Health Specialties Wellness & Lifestyle

Evaluating Digital Therapeutics for Midlife Women’s Menopausal Symptoms: A Synthesis of Recent Randomized Controlled Trials

By MedXY 08/20/2025

This review synthesizes evidence on mobile digital therapeutics targeting vasomotor and behavioral health symptoms in menopausal and midlife women, highlighting efficacy, engagement, and implications for scalable symptom management.

OB/GYN & Women's Health Specialties Wellness & Lifestyle

FDA Extends Review of Bayer’s Elinzanetant for Menopause Symptoms

By MedXY 07/28/2025

The FDA delays its review of Bayer's elinzanetant, a novel treatment for menopause-related vasomotor symptoms, by 90 days, citing the need for additional data assessment.